Literature DB >> 25083225

Does orlistat cause acute kidney injury?

Michael M Beyea, Amit X Garg, Matthew A Weir.   

Abstract

Orlistat is an inhibitor of gastric and pancreatic lipase with proven efficacy in the augmentation and maintenance of weight loss. Although its use has been limited by troublesome but benign gastrointestinal side effects, it has more recently been associated with acute kidney injury (AKI). In this review, we summarize orlistat's benefits and drawbacks and discuss the body of evidence supporting its role as a cause of AKI. Although we cannot yet draw an unequivocal causal link between orlistat and AKI, there is enough evidence to include orlistat exposure in the clinical assessment of patients with AKI.

Entities:  

Keywords:  acute kidney injury; orlistat

Year:  2012        PMID: 25083225      PMCID: PMC4110847          DOI: 10.1177/2042098611429985

Source DB:  PubMed          Journal:  Ther Adv Drug Saf        ISSN: 2042-0986


  42 in total

1.  Rapidly progressive renal failure associated with successful pharmacotherapy for obesity.

Authors:  Aisling E Courtney; Declan M O'Rourke; Alexander Peter Maxwell
Journal:  Nephrol Dial Transplant       Date:  2006-11-22       Impact factor: 5.992

Review 2.  Orlistat-associated adverse effects and drug interactions: a critical review.

Authors:  Theodosios D Filippatos; Christos S Derdemezis; Irene F Gazi; Eleni S Nakou; Dimitri P Mikhailidis; Moses S Elisaf
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

3.  Orlistat and acute kidney injury: an analysis of 953 patients.

Authors:  Matthew A Weir; Michael M Beyea; Tara Gomes; David N Juurlink; Muhammad Mamdani; Peter G Blake; Ron Wald; Amit X Garg
Journal:  Arch Intern Med       Date:  2011-04-11

4.  Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial.

Authors:  David E Kelley; George A Bray; F Xavier Pi-Sunyer; Samuel Klein; James Hill; John Miles; Priscilla Hollander
Journal:  Diabetes Care       Date:  2002-06       Impact factor: 19.112

5.  Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.

Authors:  J O Hill; J Hauptman; J W Anderson; K Fujioka; P M O'Neil; D K Smith; J H Zavoral; L J Aronne
Journal:  Am J Clin Nutr       Date:  1999-06       Impact factor: 7.045

6.  [Score of suspected drug-induced acute liver disorders. Presentation of an evaluation sheet].

Authors:  G Danan; C Benichou; A Flahault
Journal:  Gastroenterol Clin Biol       Date:  1993

7.  Meta-analysis: pharmacologic treatment of obesity.

Authors:  Zhaoping Li; Margaret Maglione; Wenli Tu; Walter Mojica; David Arterburn; Lisa R Shugarman; Lara Hilton; Marika Suttorp; Vanessa Solomon; Paul G Shekelle; Sally C Morton
Journal:  Ann Intern Med       Date:  2005-04-05       Impact factor: 25.391

8.  Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin.

Authors:  John M Miles; Lawrence Leiter; Priscilla Hollander; Thomas Wadden; James W Anderson; Michael Doyle; John Foreyt; Louis Aronne; Samuel Klein
Journal:  Diabetes Care       Date:  2002-07       Impact factor: 19.112

9.  Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study.

Authors:  H B Hubert; M Feinleib; P M McNamara; W P Castelli
Journal:  Circulation       Date:  1983-05       Impact factor: 29.690

10.  Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.

Authors:  M H Davidson; J Hauptman; M DiGirolamo; J P Foreyt; C H Halsted; D Heber; D C Heimburger; C P Lucas; D C Robbins; J Chung; S B Heymsfield
Journal:  JAMA       Date:  1999-01-20       Impact factor: 56.272

View more
  4 in total

1.  Investigation of lipase-ligand interactions in porcine pancreatic extracts by microscale thermophoresis.

Authors:  Ghassan Al Hamoui Dit Banni; Rouba Nasreddine; Syntia Fayad; Cyril Colas; Axel Marchal; Reine Nehmé
Journal:  Anal Bioanal Chem       Date:  2021-04-02       Impact factor: 4.142

2.  Efficacy of Fenugreek-based bionanocomposite on renal dysfunction and endogenous intoxication in high-calorie diet-induced obesity rat model-comparative study.

Authors:  Victoria V Konopelniuk; Ievgenii I Goloborodko; Tetyana V Ishchuk; Tetyana B Synelnyk; Ludmila I Ostapchenko; Mykola Ya Spivak; Rostyslav V Bubnov
Journal:  EPMA J       Date:  2017-06-16       Impact factor: 6.543

Review 3.  Metabolic Surgery to Treat Obesity in Diabetic Kidney Disease, Chronic Kidney Disease, and End-Stage Kidney Disease; What Are the Unanswered Questions?

Authors:  William P Martin; James White; Francisco J López-Hernández; Neil G Docherty; Carel W le Roux
Journal:  Front Endocrinol (Lausanne)       Date:  2020-08-17       Impact factor: 5.555

Review 4.  Safety and Mode of Action of Diabetes Medications in comparison with 5-Aminolevulinic Acid (5-ALA).

Authors:  Peter R Rehani; Hanaa Iftikhar; Motowo Nakajima; Tohru Tanaka; Zaid Jabbar; Riyadh N Rehani
Journal:  J Diabetes Res       Date:  2019-11-06       Impact factor: 4.011

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.